United States v. Funaro

253 F. Supp. 2d 286, 2003 U.S. Dist. LEXIS 4756, 2003 WL 1702025
CourtDistrict Court, D. Connecticut
DecidedMarch 26, 2003
DocketCRIM.3:01 CR 17 (CFD)
StatusPublished
Cited by5 cases

This text of 253 F. Supp. 2d 286 (United States v. Funaro) is published on Counsel Stack Legal Research, covering District Court, D. Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Funaro, 253 F. Supp. 2d 286, 2003 U.S. Dist. LEXIS 4756, 2003 WL 1702025 (D. Conn. 2003).

Opinion

RULING ON DEFENDANT’S MOTION TO SUPPRESS

DRONEY, District Judge.

In December 2001, a grand jury sitting in New Haven returned a 27-count Second Superseding Indictment against Edmund Funaro, Jr. (“Funaro”), a pharmacist and owner of Viséis Pharmacy (“Viséis”) in New Haven. Each count charges Funaro with illegally dispensing controlled substances in violation of 21 U.S.C. § 841(a)(1). The controlled substances included Percocet, Vicodin, Xanax, and Klo-nopin.

Pending before the Court is Funaro’s Motion to Suppress Statements and Documents [Doc. # 160]. The motion seeks suppression of statements and other evidence obtained by State of Connecticut Drug Control Agent Deborah Komososki and U.S. Drug Enforcement Administration Diversion Investigator Leonard Levin during an administrative inspection of Vi-séis on April 26, 1999. The motion also *288 seeks suppression of all statements and other evidence “derivatively obtained” from that inspection, including evidence and statements obtained during subsequent inspections and a June 6, 2000 search of Viséis pursuant to a search warrant. Funaro claims that suppression is warranted because the information was obtained in violation of his right to “substantial and fundamental fairness” as guaranteed by the Fourth and Fifth Amendments of the United States Constitution as well as federal and Connecticut state law, regulations, and procedures. For the following reasons, the motion is DENIED.

I. Findings of Fact

Viséis is located on Dixwell Avenue in New Haven, Connecticut. Funaro is a pharmacist at Viséis, as well as an owner. Dr. William Massie (“Massie”), a physician, maintained an office on Dixwell Avenue close to Viséis, and has been the subject of much attention by federal and state drug control agents, as described below. Leonard Levin (“Levin”) is a diversion investigator for the United States Drug Enforcement Administration (“DEA”) with 22 years’ experience. His duties consist primarily of preventing diversion of controlled substances into illicit markets by physicians and pharmacists. Levin is authorized to conduct inspections of pharmacies pursuant to 21 U.S.C. § 880 within a regulatory framework established by 21 C.F.R. §§ 1316.01 et seq. He does not carry a firearm and is not authorized to make arrests.

Before inspecting records at a pharmacy, a DEA agent is required to present the appropriate person at the pharmacy with a DEA Form 82 Notice of Inspection (“Form 82”). The Form 82 sets forth the registrant’s rights, including the registrant’s right to refuse an inspection without an administrative inspection warrant 1 and advises that evidence found during the inspection may be used against the registrant in a criminal prosecution.

Deborah Komoroski (“Komoroski”) is an agent of the State of Connecticut Department of Consumer Protection, Drug Control Division (“State Drug Control”) with approximately 15 years’ experience. Like Agent Levin, her duties include monitoring the flow of legal drugs through legitimate channels in order to prevent illegal diversion of those drugs.

State Drug Control agents conduct audits and inspections of pharmacies and other entities under laws of the State of Connecticut which are similar to the federal regulatory scheme, except that State Drug Control agents are also authorized to serve search and arrest warrants. Under Connecticut law, pharmacies are required to permit State Drug Control agents to have access to records relating to their receipt and distribution of controlled substances. Also, when a State Drug Control agent enters a pharmacy to conduct an audit or an inspection, the agent is not required under Connecticut law to provide any form or other notification to the owner or operator of the pharmacy. State Drug Control agents are also directed by Connecticut statute to cooperate with other agencies in enforcing laws of the United States relating to controlled substances.

State Drug Control audits are administratively assigned in July of each year. State Drug Control agents are not involved with DEA Form 82s except when *289 the State Drug Control agent is accompanying a DEA agent.

1987 State Drug Control/DEA Investigation of Massie

Massie was first investigated in 1987 by State Drug Control and DEA. At that time, Massie did not have a valid Connecticut Controlled Substance Registration or a federal DEA Registration. In connection with the 1987 investigation of Massie, State Drug Control and DEA agents visited several pharmacies in the New Haven area, including Viséis. Neither Viséis nor Funaro was a subject or target of the 1987 investigation of Massie. No other violations were discovered relating to Massie during the 1987 investigation except the lack of the controlled substance registrations. The State Department of Consumer Protection concluded the 1987 investigation of Massie by issuing him a controlled substances certificate of registration,, as did DEA.

April 1998 Audit of Viséis

In 1997, Komoroski was assigned to conduct a regular audit of Viséis. The audit was begun in April 1998 by Komoroski and State Drug Control Agent Barry Gordon (“Gordon”). No DEA investigators were present at that audit.

In the course of the April 1998 audit, the agents reviewed Viséis’ handling of several controlled substances, including Percocet, Ritalin, Xanax, and Vicodin. The audit revealed shortages of some of the controlled substances in ranges between approximately six and 12 percent. When State Drug Control conducts an audit of a pharmacy’s controlled substances, it deems an overage or a shortage of three to five percent as an acceptable range. Anything above five percent requires additional inquiry, which may include the scheduling of another audit a year later. State Drug Control did not initiate a criminal investigation of Viséis or Funaro as a result of the shortages found in the April 1998 audit. Rather, on July 2, 1998, State Drug Control scheduled a follow-up audit audit of Viséis to occur the next year in order to determine whether the problems revealed by the April 1998 audit had been resolved. Komoroski was assigned to conduct this follow-up audit of Viséis.

1998-99 Criminal Investigation of Mas-sie

Beginning in June 1998 and continuing into 1999, State Drug Control, in conjunction with DEA and other agencies, conducted a new criminal investigation of Massie concerning his prescribing controlled substances.

Komoroski did not work on the 1998-99 criminal investigation of Massie. The case was assigned to State Drug Control Agent John Gadea (“Gadea”). However, DEA Agent Levin became involved in the 1998-99 criminal investigation of Massie in the late summer or early fall of 1998. Viséis was not a subject or target of the 1998-99 criminal investigation of Dr. Massie. The investigation was not fruitful and investigative efforts were terminated in early 1999.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Mansour
252 F. Supp. 3d 182 (W.D. New York, 2017)
United States v. Chandler
164 F. Supp. 3d 368 (E.D. New York, 2016)
United States v. Gigliotti
145 F. Supp. 3d 203 (E.D. New York, 2015)
United States v. Wilson
100 F. Supp. 3d 268 (E.D. New York, 2015)
United States v. Carr
63 F. Supp. 3d 226 (E.D. New York, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
253 F. Supp. 2d 286, 2003 U.S. Dist. LEXIS 4756, 2003 WL 1702025, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-funaro-ctd-2003.